CompletedPhase 3

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

United States122 participantsStarted 2019-05-02

Plain-language summary

This is an investigator initiated, multicenter, open label, randomized phase 3 study for subjects with newly diagnosed ITP from ages 1 to less than 18 years old.

Who can participate

Age range1 Year – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Upfront treatment: Patient within 10 days of ITP diagnosis who has not received previous treatment OR
✓. Treatment failure: Patients who have failed standard management (observation or treatment with one or more first-line agents)

What they're measuring

Proportion of Patients With a Platelet Response

Timeframe: 12 weeks

Trial details

NCT IDNCT03939637

SponsorBaylor College of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-04-17

Results submitted2025-06-24

View on ClinicalTrials.gov More Immune Thrombocytopenia trials